IN8BIO, INC. (INAB) Form 8-K — Aug 6, 2026
IN8bio reported a second quarter 2026 net loss of $4.8 million, or $0.25 per basic and diluted share, compared with a $5.1 million loss, or $1.24 per share, in the prior-year quarter. R&D expense was flat at $2.5 million and G&A expense declined to $2.4 million from $2.7 million. Cash stood at $18.0 million as of June 30, 2026, up from $13.2 million a year earlier but down from $27.1 million at December 31, 2025. With roughly $9.9 million lost in the first half of 2026, the company's risk factors explicitly flag its ability to raise additional capital and to continue operating as a going concern.
Key figures
- Total Assets
- 21745000
- Cash Position
- 18000000
- Shares Outstanding
- 9853121
- Cash Dec31 2025
- $27.1 million
- Mos Delt Ex Vs Soc
- 19.5+ months vs 13.2 months for standard of care
- Mpfs Delt Ex Vs Soc
- 13.0 months vs 6.6 months for standard of care
- Ga Expense Q2 2026
- $2.4 million (vs $2.7 million prior year)
- Rd Expense Q2 2026
- $2.5 million (vs $2.5 million prior year)
- Net Loss Prior Year Q2
- $5.1 million, or $1.24 per basic and diluted share
- Survival At24 Months
- 43% of repeat-dose patients alive vs 20% of SOC patients
- Net Loss Six Months2026
- $9.9 million ($9,871 thousand)
- Cd8 TCell Density Increase
- 18-fold intratumoral increase per spatial proteomics
- Weighted Avg Shares Q2 2026
- 19467091
- Immunosuppressive Granulocyte Reduction
- 90%
Price after filing
Close on the filing date to close N calendar days later (from $0.96). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.